Madison Avenue Group Reports 9.7% Stake in SAGE (6.08M Shares)
Rhea-AI Filing Summary
The Reporting Persons — Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha — disclosed beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock, representing approximately 9.7% of the 62,620,694 shares used as the basis for the calculation. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power claimed.
The statement was filed on Schedule 13G, indicating a passive stake, and includes a certification that the securities were not acquired to change or influence control of the issuer.
Positive
- Material disclosure of 6,077,065 shares (approximately 9.7% of the class), which provides transparency to the market
- Filed on Schedule 13G, indicating the Reporting Persons represent a passive stake and include a certification they are not seeking to change control
Negative
- None.
Insights
TL;DR A substantial passive position of 9.7% is disclosed, notable for size but presented as non-control.
The reported 6,077,065-share position is material relative to outstanding stock and is large enough to influence trading dynamics or trigger investor attention. The Schedule 13G form and the certification that the securities were not acquired to change control suggest the Reporting Persons intend a passive investment stance rather than activist engagement. For investors, the key implications are transparency of ownership and potential for market impact without an explicit governance agenda.
TL;DR Group ownership near 10% requires monitoring, but Schedule 13G filing signals passive intent and no declared control attempt.
The aggregated ownership by related entities and an individual highlights a connected ownership structure where Madison Avenue-affiliated entities and Eli Samaha are deemed beneficial owners. The filing discloses shared voting and dispositive power, not sole control. Governance risk is limited by the explicit certification denying control-seeking purposes, yet the economic stake remains significant and merits attention to any future amendments or Schedule 13D filings.
FAQ
Who filed the Schedule 13G/A for Sage Therapeutics (SAGE)?
How many SAGE shares do the Reporting Persons beneficially own?
What percentage of SAGE does the disclosed stake represent?
Does the Schedule 13G/A indicate an intent to influence control of SAGE?
What voting and dispositive powers are reported for the stake?